What'sNearbyTM

What are you looking for?

Close Search
      We apologize for the inconvenience

      The people search feature on Superpages.com is temporarily unavailable. You can still search for people on yellowpages.com since Yellow Pages and Superpages are part of one company.

      You will be automatically re-directed to People Search on yellowpages.com in .

      Cmc Icos Biologics Inc.

      Add to Favorites
      Be the first to review!
      Marketing Consultants, Marketing Programs & Services

      22021 20th Ave SE, Bothell, WA 98021

      425-485-1900

      OPEN NOW: 
      Today: 8:00 am - 5:00 pm
      CallWebsite

      REVIEWS write reviewWrite a Review

      Be the first to review!
      First-classBetter than mostAbout what I expectedNot the worst...Disappointing
      DETAILS
      General Info
      Founded in 1990, CMC ICOS Biologics aims at discovering, developing and marketing therapeutic products. CMC ICOS Biologics works toward developing treatments for medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer and inflammatory diseases. The company has a joint venture with Eli Lilly and Company and markets its product Cialis for the treatment of erectile dysfunction. The company also manufactures Tadalafil for treating the enlargement of the prostate and IC485 chronic obstructive pulmonary disease. The company has expertise in cell line and process development and specializes in delivering protein-based materials and recombinant protein products for preclinical and clinical trials. CMC ICOS Biologics is headquartered in Bothell, Wash.
      Extra Phones

      Phone: 425-485-8064

      Phone: 425-485-0280

      Fax: 425-489-0356

      Hours
      Regular Hours
      Mon - Fri:
      Categories
      Marketing Consultants, Marketing Programs & Services
      AKA

      CMC Biologics Inc

      Other Link

      http://www.cmcbio.com

      Suggest an Edit
      Data provided by one or more of the following: Thryv, Data Axle, Yext.